Biogen (BIIB) announced that BIIB122, a LRRK2 inhibitor for Parkinson’s disease developed in collaboration with Denali Therapeutics, Phase 2b LUMA study has fully enrolled with a readout expected in 2026. Today Biogen also announced that it plans to host a series of investor events to highlight the development pipeline. Biogen plans to hold the first virtual event on June 11 at 10 a.m. ET with a focus on felzartamab and rare disease. “Biogen does not intend to disclose new clinical data on the call,” it stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue